COST-EFFECTIVENESS OF NIVOLUMAB FOR THE TREATMENT OF ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC) IN SAUDI ARABIA

被引：1
|
作者：
Alhammad, A. [1 ]
Lecca, Garrido S. [2 ]
机构：
[1] King Abdul Aziz Med City, Riyadh, Saudi Arabia
[2] Bristol Myers Squibb, Dubai, U Arab Emirates
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.2254
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN181
引用
收藏
页码：A741 / A741
页数：1
相关论文
共 50 条
  • [31] KRAS molecular profiling in non-squamous non-small cell lung cancer (NSCLC).
    Karim, Nagla Abdel
    Starnes, Sandra
    Morris, John
    Pathrose, Peter
    Perry, Ashley
    Fathallah, Hassana
    CLINICAL CANCER RESEARCH, 2014, 20
  • [32] COST-EFFECTIVENESS OF FIRST-LINE THERAPY FOR ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)
    Yang, M. C.
    Tan, E. C. H.
    VALUE IN HEALTH, 2014, 17 (07) : A736 - A736
  • [33] PEMETREXED MAINTENANCE TREATMENT IN ADVANCED NON SQUAMOUS NON-SMALL CELL LUNG CANCER (NSCLC)
    Megaiz, Ahlem
    Bousahba, Abdelkader
    Rabah, Aicha
    Zemmour, Amel
    Ahed-Messaoud, Malika
    Ghazli, Soumia
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S588 - S589
  • [34] COST-EFFECTIVENESS OF IMMUNOTHERAPY-BASED DRUG REGIMENS FOR THE INITIAL TREATMENT OF PATIENTS WITH METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG CANCER
    Aggarwal, H.
    Zhang, S.
    Muehlenbein, C. E.
    Winfree, K. B.
    Zhu, Y.
    Baker, T.
    VALUE IN HEALTH, 2019, 22 : S453 - S454
  • [35] Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Ding, Dong
    Hu, Huabin
    Liao, Mengting
    Shi, Yin
    She, Longjiang
    Yao, Linli
    Zhu, Youwen
    Zeng, Shan
    Huang, Jin
    ADVANCES IN THERAPY, 2020, 37 (05) : 2116 - 2126
  • [36] Cost-Effectiveness Analysis of Atezolizumab Plus Chemotherapy in the First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
    Dong Ding
    Huabin Hu
    Mengting Liao
    Yin Shi
    Longjiang She
    Linli Yao
    Youwen Zhu
    Shan Zeng
    Jin Huang
    Advances in Therapy, 2020, 37 : 2116 - 2126
  • [37] Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer
    Keating, Gillian M.
    DRUGS, 2015, 75 (16) : 1925 - 1934
  • [38] Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer
    Gillian M. Keating
    Drugs, 2015, 75 : 1925 - 1934
  • [39] First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China
    Yang, Zhiguang
    Zhu, Yumei
    Xiang, Guiyuan
    Hua, Tiantian
    Ni, Jun
    Zhao, Jie
    Lu, Yun
    Wu, Yingyu
    Chang, Feng
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2021, 21 (05) : 1061 - 1067
  • [40] Phase II Studies of Nivolumab in Patients with Advanced Squamous (SQ) or Non-Squamous (NSQ) Non-Small-Cell Lung Cancer (NSCLC)
    Nakagawa, Kazuhiko u
    Nishio, Makoto
    Hida, Toyoaki
    Sakai, Hiroshi
    Nogami, Naoyuki
    Atagi, Shinji
    Takahashi, Toshiaki
    Nokihara, Hiroshi
    Saka, Hideo
    Takenoyama, Mitsuhiro
    Fujita, Shiro
    Tanaka, Hiroshi
    Takeda, Koji
    Satouchi, Miyako
    Isobe, Hiroshi
    Maemondo, Makoto
    Goto, Koichi
    Hirashima, Tomonori
    Minato, Koichi
    Tamura, Tomohide
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S270 - S271
12345